- In its latest reported quarter, CONMED posted 7.9% year-on-year revenue growth that exceeded analyst expectations, but its full-year revenue and EPS fell short of prior guidance, highlighting operational and forecasting challenges in a complex medtech environment.
- This mix of a solid quarterly performance and weaker full-year guidance underscores the tension between near-term execution and investor concerns about the company’s longer-term growth trajectory.
- Next, we’ll examine how strong fourth-quarter revenue alongside missed full-year guidance may reshape CONMED’s investment narrative and risk profile.
Find 58 companies with promising cash flow potential yet trading below their fair value.
CONMED Investment Narrative Recap
To own CONMED, you need to believe in sustained demand for minimally invasive surgery tools and the company’s ability to turn that demand into healthier margins over time. The latest quarter’s 7.9% revenue growth supports the demand side, but the miss on full‑year revenue and EPS guidance keeps the biggest near term risk front and center: execution and forecasting discipline. For now, this news reinforces rather than materially changes that core risk and the key catalyst of operational improvement.
Among recent developments, CONMED’s December 2025 decision to exit gastroenterology product lines stands out as most relevant. It tightens the company’s focus on core areas like minimally invasive, robotic and laparoscopic surgery, smoke evacuation and orthopedic soft tissue treatment, which are central to the growth thesis behind products such as AirSeal and BioBrace. In the context of a guidance miss, this portfolio refocus may become an important test of whether management can simplify the business and support more reliable performance.
Yet behind the promising Q4 revenue beat, investors should be aware of how supply chain strains and rising cost pressures could still...
Read the full narrative on CONMED (it's free!)
CONMED's narrative projects $1.6 billion revenue and $154.0 million earnings by 2028. This requires 5.7% yearly revenue growth and about a $43.8 million earnings increase from $110.2 million today.
Uncover how CONMED's forecasts yield a $48.40 fair value, a 32% upside to its current price.
Exploring Other Perspectives
Before this earnings miss, the most cautious analysts were assuming about US$1.5 billion of revenue and US$127.4 million of earnings by 2028, so compared with concerns about rising global healthcare cost controls and reimbursement pressure, their narrative paints a much more constrained outlook that you should weigh alongside more optimistic views, especially as fresh results may prompt both camps to rethink their assumptions.
Explore 3 other fair value estimates on CONMED - why the stock might be worth just $39.00!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your CONMED research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
- Our free CONMED research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CONMED's overall financial health at a glance.
Looking For Alternative Opportunities?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
- Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com